| DB ID | MyCo_3521 |
| Title | (1,3)-β-D-glucan is able to predict therapeutic failure of patients with candidemia and not only mortality |
| Year | 2020 |
| PMID | 33274533 |
| Fungal Diseases involved | Candidemia |
| Associated Medical Condition | Cardiovascular Disease |
| Genus | Candida |
| Species | spp. |
| Organism | Candida spp. |
| Ethical Statement | The authors confirm that the ethical policies of the journal have been adhered to and the appropriate ethical review committee approval from Escola Paulista de Medicina, Universidade Federal de Sao Paulo (CEP-UNIFESP 804.657) was received. |
| Site of Infection | None |
| Opportunistic invasive | Opportunistic |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | BDG |
| Biomarker Full Name | 1-3-beta-D-Glucan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Brazil |
| Cohort | This was a prospective study where the investigators collected volumes of 5-8 ml at baseline (first day of positive blood culture for Candida species) after obtaining the informed consent of all enrolled patients with microbiologic documented fungemia. Samples were screened at 2 tertiary care university-affiliated centers in São Paulo (Hospital São Paulo- Hospital do Rim e Hipertensão) and Rio de Janeiro (Hospital Universitário Clementino Fraga Filho). The study was approved by the Ethic Committee of all hospitals. Patients with at least one positive blood culture for Candida spp. between June 1st, 2010 and February 28th, 2015 were identified by daily visits to the central microbiology laboratory of each institution. Patients younger than 18 years and those who died before blood cultures became positive were excluded. Here enrolled a total of 71 patients with candidemia and a control group with 110 healthy volunteers. |
| Cohort No. | 71 Patients and 110 Controls |
| Age Group | 18-87 |
| P Value | None |
| Sensitivity | 71.80% |
| Specificity | 98.20% |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Candidemia is a major cause of bloodstream infection in tertiary care hospitals worldwide and is associated with high morbidity and mortality. Fungal biomarkers may be more sensitive than blood cultures and enable faster diagnosis of candidemia with a positive impact on the outcome. |
| Technique | Assay |
| Analysis Method | Fungitell assay |
| ELISA kits | None |
| Assay Data | FDA- Fungitell® assay (Associates of Cape Cod, Falmouth - USA) |
| Validation Techniques used | Fungitell assay |
| Up Regulation Down Regulation | Increase |
| Sequence Data | None |
| External Link | None |
